Scholarlink

Purpose <p>Patients with endometrial cancer (EC), a prevalent gynecologic cancer in the United States, and benign gynecological conditions such as fibroids and endometriosis, experience poor quality of life (QOL). Organisms in vaginal and rectal microbiomes have been previously linked to both adverse symptoms and gynecologic disease. Using gastrointestinal, mental, physical, and sexual health symptoms as a proxy for QOL, we explored QOL relationships with vaginal and rectal microbes between patients with EC and benign gynecological conditions.</p> Methods <p>Patients undergoing hysterectomy for benign or oncological indications at a single center completed QOL surveys preoperatively. The operating surgeon collected vaginal and rectal swabs prior to surgery. Survey and microbiome data were analyzed separately and then correlated utilizing MicrobiomeAnalyst, analysis of compositions of microbiomes with bias correction (ANCOM-BC), and GraphPad Prism 10.2.3.</p> Results <p>Sexual interest and Vaginal Assessment Scale (VAS) scores were higher in the benign group. Vaginal species richness was higher in the EC group. Vaginal <i>Porphyromonas</i> negatively correlated to sexual interest in all patients, while <i>Dialister B</i> positively correlated to sexual interest in the benign group. Patients with EC and worse vaginal atrophy had increased vaginal <i>L. iners</i>, despite adjustment for menopausal status. In the rectal microbiome, Gastranaerophilales positively correlated to good mental health and Verrucomicrobiales negatively correlated to vulvar symptoms.</p> Conclusion <p>Identifying microbiome signatures that impact QOL in patients with EC and benign gynecological conditions increases understanding of how microbes may influence patient wellbeing. We offer preliminary findings for foundational knowledge for future opportunities on improvement of QOL through microbiome modulation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Microbiome impacts quality of life in patients with endometrial cancer and benign gynecological conditions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月19日

查看全文
  • Nina J. Gautam,
  • Nicole R. Jimenez,
  • Paweł Łaniewski,
  • Haiyan Cui,
  • Denise J. Roe,
  • Dana M. Chase,
  • Melissa M. Herbst-Kralovetz

摘要

Purpose

Patients with endometrial cancer (EC), a prevalent gynecologic cancer in the United States, and benign gynecological conditions such as fibroids and endometriosis, experience poor quality of life (QOL). Organisms in vaginal and rectal microbiomes have been previously linked to both adverse symptoms and gynecologic disease. Using gastrointestinal, mental, physical, and sexual health symptoms as a proxy for QOL, we explored QOL relationships with vaginal and rectal microbes between patients with EC and benign gynecological conditions.

Methods

Patients undergoing hysterectomy for benign or oncological indications at a single center completed QOL surveys preoperatively. The operating surgeon collected vaginal and rectal swabs prior to surgery. Survey and microbiome data were analyzed separately and then correlated utilizing MicrobiomeAnalyst, analysis of compositions of microbiomes with bias correction (ANCOM-BC), and GraphPad Prism 10.2.3.

Results

Sexual interest and Vaginal Assessment Scale (VAS) scores were higher in the benign group. Vaginal species richness was higher in the EC group. Vaginal Porphyromonas negatively correlated to sexual interest in all patients, while Dialister B positively correlated to sexual interest in the benign group. Patients with EC and worse vaginal atrophy had increased vaginal L. iners, despite adjustment for menopausal status. In the rectal microbiome, Gastranaerophilales positively correlated to good mental health and Verrucomicrobiales negatively correlated to vulvar symptoms.

Conclusion

Identifying microbiome signatures that impact QOL in patients with EC and benign gynecological conditions increases understanding of how microbes may influence patient wellbeing. We offer preliminary findings for foundational knowledge for future opportunities on improvement of QOL through microbiome modulation.